Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Entocort for Children With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit.~* Subject must be diagnosed with active Crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology.~* Subjects with mild to moderate Crohn's disease.~* All subjects must have a stool analysis negative for Clostridium difficile toxin, Yersinia enterolytica, Campylobacter jejuni, Salmonella, Shigella, within the 30 days prior to visit 1.~* All subjects must have had laboratory assessments within 7 days prior to visit 1.~* All subjects must weigh \>= 15 kg at time of enrollment~Exclusion Criteria:~* Subjects who have had any previous intestinal resection proximal to and including the ascending colon~* Subjects with evidence of severe active Crohn's disease and/or, stricturing and prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications~* Subjects who do not have a negative stool analysis, within the 30 days prior to visit 1~* Subjects who have been screened/or enrolled in this study previously within the last 30 days~* Subjects with morning cortisol level \<150 nmol/l (5.4 ug/dl) or DHEA-S below normal range for age and gender

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Entocort (Type: EXPERIMENTAL): Study Medication

Based on this trial design, predict the completion outcome and termination type (if applicable).